REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
11/01/2025
Back to search
Official data from USPTO
AB ACUMEN BIOPHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
11/02/2025
Trademark type
Combined
Nice classes
42, 45
Filing date
11/10/2015
Registration date
11/01/2016
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/02/2023
Last transaction
11/02/2025
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
First use anywhere
01/13/2012
First use in commerce
01/13/2012
Drawing code
5
Owner type
16
Owner location
Pennington, NJ
Examiner
STRINGER, DANIEL
Law office
L30
Current location
TMEG LAW OFFICE 103
Mark description
The mark consists of the stylized wording "ACUMEN BIOPHARMA" to the right of the interconnected, stylized letters "AB". A partial mirror image of the interconnected letters "AB" appear directly below the interconnected letters "AB".
Holders and representatives
Holders
Acumen BioPharma, LLC
Representatives
Elyse A Marcus SILLS CUMMIS & GROSS P.C.
Technical classification
Nice Classes
Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Consulting services for others in the field of pharmaceutical researchlaboratory testing and project management of scientific research and laboratory testing
Class 45
Expert witness services in legal matters in the field of pharmaceuticals and patent litigation
Publications
History of USPTO decisions and trademark events.
29 publications found
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
03/02/2023
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
03/02/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/02/2023
E815
TEAS SECTION 8 & 15 RECEIVED
08/15/2022
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
11/01/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
11/01/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/16/2016
PUBO
PUBLISHED FOR OPPOSITION
08/16/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/27/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
07/08/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/01/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/23/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/23/2016
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
06/21/2016
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
05/16/2016
GNFR
FINAL REFUSAL E-MAILED
05/16/2016
CNFR
FINAL REFUSAL WRITTEN
05/16/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/11/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/11/2016
ALIE
ASSIGNED TO LIE
05/05/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/22/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/08/2016
GNRT
NON-FINAL ACTION E-MAILED
03/08/2016
CNRT
NON-FINAL ACTION WRITTEN
03/08/2016
DOCK
ASSIGNED TO EXAMINER
03/02/2016
MPMK
NOTICE OF PSEUDO MARK E-MAILED
11/17/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/14/2015
NWAP
NEW APPLICATION ENTERED
11/13/2015
Continuous trademark protection
Get notified about every new filing that threatens AB ACUMEN BIOPHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.